Advisory Services Network’s Madrigal Pharmaceuticals MDGL Stock Holding History

Advisory Services Network’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$250K	Hold	466	–	–	﹤0.01%	1852
2026 Q1	$244K	Sell	466 -192	-29%	-$91.7K	﹤0.01%	1703
2025 Q4	$383K	Buy	+658	New	+$336K	0.01%	1345

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Advisory Services Network's MDGL Position: Q2 2026 in Review

Advisory Services Network held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 466 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #1852.

Advisory Services Network first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $383K in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Advisory Services Network held 466 shares of Madrigal Pharmaceuticals worth $250K as of Q2 2026.
Advisory Services Network left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Advisory Services Network's portfolio in Q2 2026, its #1852 holding.
Advisory Services Network first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
Advisory Services Network's Madrigal Pharmaceuticals position peaked at $383K in Q4 2025.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.